The most common grade 3–4 adverse reactions related to treatment with rucaparib (>1% of patients) were anemia (19%), AST or ALT increase (10%), neutropenia (7%), fatigue (7%), thrombocytopenia (5%), nausea (4%), vomiting (4%), constipation (2%), and abdominal pain (2%). Here, GPT is linked to anemia.